Q3 2025 Abbott Laboratories Earnings Call Transcript
Key Points
- Abbott Laboratories (ABT) reported a strong organic sales growth of 7.5%, excluding COVID test sales, with significant contributions from medical devices and established pharmaceuticals.
- Earnings per share rose to $1.30, reflecting high single-digit growth compared to the previous year, and double-digit growth when excluding the decline in COVID test sales.
- The company's performance is driven by innovation, with new products generating nearly half a billion dollars in sales this quarter, adding over 100 basis points to organic sales growth.
- Abbott Laboratories (ABT) continues to invest in its nutrition brands, launching new versions of Glucerna and Ensure to align with changing consumer preferences.
- The medical devices segment saw a 12.5% sales growth, driven by double-digit growth in diabetes care, electrophysiology, cardiac rhythm management, heart failure, and structural heart.
- Challenging market conditions in China, particularly affecting price and volume, remain a headwind for Abbott Laboratories (ABT)'s core lab diagnostic business.
- The company experienced a decline in COVID test sales, which impacted overall earnings growth.
- Foreign exchange had a less favorable impact on third-quarter sales than forecasted, affecting the financial results.
- The adjusted gross margin decreased compared to the prior year due to the impact of tariffs.
- Abbott Laboratories (ABT) faced competitive pressures in the US pediatric nutrition market, leading to some share losses.
Good morning and thank you for standing by. Welcome to Abbott's third quarter, 2025 earnings conference call. All participants will be able to listen-only until the question-and-answer portion of this call.
During the question-and-answer session, you will be able to ask your question by pressing the 11 keys on your touch tone phone.
This call is being recorded by Abbott. With the exception of any participants questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission.
I would now like to introduce Mr. Mike Camilla, Vice President, Investor relations.
Good morning and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreaux, Executive Vice President, finance and Chief Financial Officer.
Robert and Phil will provide opening
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
